BRAFV600E and KIT immunoexpression in early-stage melanoma

Olsen CM, 2010, Estimating the attributable fraction for cancer: A meta-analysis of nevi and melanoma, Cancer Prev Res (Phila), 3, 233, 10.1158/1940-6207.CAPR-09-0108 Rajkumar S, 2016, Molecular characterisation of cutaneous melanoma: creating a framework for targeted and immune therapies, Br J Cancer, 115, 145, 10.1038/bjc.2016.195 Bastian BC, 2014, The molecular pathology of melanoma: an integrated taxonomy of melanocytic neoplasia, Annu Rev Pathol, 9, 239, 10.1146/annurev-pathol-012513-104658 Joyce KM, 2015, An assessment of histological margins and recurrence of melanoma in situ, Plast Reconstr Surg Glob Open, 3, 10.1097/GOX.0000000000000272 Mihic-Probst D, 2016, Update on Thin Melanoma: Outcome of an International Workshop, Adv Anat Pathol, 23, 24, 10.1097/PAP.0000000000000100 Griffin M, 2017, BRAF inhibitors: Resistance and the promise of combination treatments for melanoma, Oncotarget, 8, 78174, 10.18632/oncotarget.19836 2015, Genomic Classification of Cutaneous Melanoma, Cell, 161, 1681, 10.1016/j.cell.2015.05.044 Ecsedi S, 2014, DNA methylation characteristics of primary melanomas with distinct biological behaviour, PLoS One, 9, 10.1371/journal.pone.0096612 Chapman PB, 2011, Improved survival with vemurafenib in melanoma with BRAF V600E mutation, N Engl J Med, 364, 2507, 10.1056/NEJMoa1103782 Mar VJ, 2015, The role of BRAF mutations in primary melanoma growth rate and survival, Br J Dermatol, 173, 76, 10.1111/bjd.13756 Shain AH, 2016, From melanocytes to melanomas, Nat Rev Cancer, 16, 345, 10.1038/nrc.2016.37 Posch C, 2016, Pharmacological inhibitors of c-KIT block mutant c-KIT mediated migration of melanocytes and melanoma cells in vitro and in vivo, Oncotarget, 7, 45916, 10.18632/oncotarget.10001 Montagnani V, 2016, Thin and thick primary cutaneous melanomas reveal distinct patterns of somatic copy number alterations, Oncotarget, 7, 30365, 10.18632/oncotarget.8758 Neiswender JV, 2017, KIT Suppresses BRAFV600E-Mutant Melanoma by Attenuating Oncogenic RAS/MAPK Signaling, Cancer Res, 77, 5820, 10.1158/0008-5472.CAN-17-0473